Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 4:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 4:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Zacks News
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Avanos Medical (AVNS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cerner (CERN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) second-quarter results are likely to reflect gains from strategic deals.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
What's in Store for Intuitive Surgical's (ISRG) Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance at Instruments & Accessories segment.
Here's Why You Should Retain Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Here's Why You Should Hold on to Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.78% and 2.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.
Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.
Avanos Medical (AVNS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 27.27% and 0.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why You Should Retain Avanos Medical (AVNS) Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.
Why Is Avanos Medical (AVNS) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.
Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 50.00% and 11.94%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.